1. Selich, A. et al. Umbilical cord as a long-Term source of activatable mesenchymal stromal cells for immunomodulation. Stem Cell Res. Ther. 10, 1–14 (2019).
2. Nekanti, U. et al. Optimization and scale-up of Wharton’s jelly-derived mesenchymal stem cells for clinical applications. Stem Cell Res. 5, 244–254 (2010).
3. Ding, D. C., Chang, Y. H., Shyu, W. C. & Lin, S. Z. Human umbilical cord mesenchymal stem cells: A new era for stem cell therapy. Cell Transplant. 24, 339–347 (2015).
4. DAVIES, J. E., WALKER, J. T. & KEATING, A. concise Review : Heart Regeneration and the Role of Cardiac Stem Cells. Stem Cells Transl. Med. 6, 1620–1630 (2017).
5. Otte, A., Bucan, V., Reimers, K. & Hass, R. Mesenchymal stem cells maintain long-term in vitro stemness during explant culture. Tissue Eng. - Part C Methods 19, 937–948 (2013).
6. Zhao, Q. et al. Systematic comparison of hUC-MSCs at various passages reveals the variations of signatures and therapeutic effect on acute graft-versus-host disease. Stem Cell Res. Ther. 10, 1–14 (2019).
7. Kamal, M. M. & Kassem, D. H. Therapeutic Potential of Wharton’s Jelly Mesenchymal Stem Cells for Diabetes: Achievements and Challenges. Front. Cell Dev. Biol. 8, 1–15 (2020).
8. Varaa, N., Azandeh, S., Khodabandeh, Z. & Gharravi, A. M. Wharton’s Jelly mesenchymal stem cell: Various protocols for isolation and differentiation of hepatocyte-like cells; narrative review. Iran. J. Med. Sci. 44, 437–448 (2019).
9. Turnbull, M. T., Zubair, A. C., Meschia, J. F. & Freeman, W. D. Mesenchymal stem cells for hemorrhagic stroke: status of preclinical and clinical research. npj Regen. Med. 4, 1–10 (2019).
10. Cabrera-Pérez, R. et al. Osteogenic commitment of Wharton’s jelly mesenchymal stromal cells: Mechanisms and implications for bioprocess development and clinical application. Stem Cell Res. Ther. 10, 1–11 (2019).
11. Dessels, C., Alessandrini, M. & Pepper, M. S. Factors Influencing the Umbilical Cord Blood Stem Cell Industry: An Evolving Treatment Landscape. Stem Cells Transl. Med. 7, 643–650 (2018).
12. Abbaszadeh, H., Ghorbani, F., Derakhshani, M., Movassaghpour, A. & Yousefi, M. Human umbilical cord mesenchymal stem cell-derived extracellular vesicles: A novel therapeutic paradigm. J. Cell. Physiol. 235, 706–717 (2020).
13. Fujita, Y., Kadota, T., Araya, J., Ochiya, T. & Kuwano, K. Clinical Application of Mesenchymal Stem Cell-Derived Extracellular Vesicle-Based Therapeutics for Inflammatory Lung Diseases. J. Clin. Med. 7, 355 (2018).
14. Vellasamy, S., Sandrasaigaran, P., Vidyadaran, S., George, E. & Ramasamy, R. Isolation and characterisation of mesenchymal stem cells derived from human placenta tissue. World J. Stem Cells 4, 53 (2012).
15. Pikuła, M., Marek-Trzonkowska, N., Wardowska, A., Renkielska, A. & Trzonkowski, P. Adipose tissue-derived stem cells in clinical applications. Expert Opin. Biol. Ther. 13, 1357–1370 (2013).
16. Lu, L.-L. et al. Isolation and characterization of human umbilical cord mesenchymal stem cells with hematopoiesis-supportive function and other potentials. Hematop. Stem Cells 91, (2006).
17. Fong, C.-Y. et al. Human Wharton’s Jelly Stem Cells Have Unique Transcriptome Profiles Compared to Human Embryonic Stem Cells and Other Mesenchymal Stem Cells. Stem Cell Rev. 7, 1–16 (2011).
18. Hsieh, J.-Y., Fu, Y.-S., Chang, S.-J., Tsuang, Y.-H. & Wang, H.-W. Mesenchymal stem cells from bone marrow and Wharton’s jelly of umbilical cord. Stem Cells Dev 19, 1895–1910 (2010).
19. Deuse, T. et al. Immunogenicity and immunomodulatory properties of umbilical cord lining mesenchymal stem cells. Cell Transplant. 20, 655–667 (2011).
20. Monguió-Tortajada, M. et al. Mesenchymal stem cells induce expression of CD73 in human monocytes in vitro and in a swine model of myocardial infarction in vivo. Front. Immunol. 8, 1–13 (2017).
21. Aung, S.-W., Kasim, N. H. A. & Ramasamy, T. S. Isolation, Expansion, and Characterization of Wharton’s Jelly-Derived Mesenchymal Stromal Cell: Method to Identify Functional Passages for Experiments. methods mol biol. 257–284 (2019) doi:10.1007/7651.
22. Mennan, C. et al. Isolation and characterisation of mesenchymal stem cells from different regions of the human umbilical cord. Biomed Res. Int. 2013, (2013).
23. Ishige, I. et al. Comparison of mesenchymal stem cells derived from arterial, venous, and Wharton’s jelly explants of human umbilical cord. Int. J. Hematol. 90, 261–269 (2009).
24. Russo, E. et al. Energy Metabolism Analysis of Three Different Mesenchymal Stem Cell Populations of Umbilical Cord Under Normal and Pathologic Conditions. Stem Cell Rev. Reports (2020) doi:10.1007/s12015-020-09967-8.
25. Chen, W. C. W. et al. Overview of the Purification of Recombinant Proteins. vol. 33 (2016).
26. Tsagias, N., Koliakos, I., Karagiannis, V., Eleftheriadou, M. & Koliakos, G. G. Isolation of mesenchymal stem cells using the total length of umbilical cord for transplantation purposes. Transfus. Med. 21, 253–261 (2011).
27. Azandeh, S. et al. Mixed enzymatic-explant protocol for isolation of mesenchymal stem cells from Wharton’s jelly and encapsulation in 3D culture system. J. Biomed. Sci. Eng. 05, 580–586 (2012).
28. Dominici, M. et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8, 315–317 (2006).
29. Hashemitabar, M. et al. Isolation and Characterization of Human Umbilical Cord Mesenchymal Stem Cells and Their Differentiation into Pdx-1+ Cells. J. Biomed. Sci. Eng. 08, 780–788 (2015).
